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ABSTRACT
Objectives: The aim of the present study was to compare the obstetric results in women with GDM in a Polish population 
based on the criterion for the diagnosis of GDM.
Material and methods: The study was a questionnaire study covering the data of 2853 patients with GDM treated in 
centers nationwide in the years 2011–2013. The principles of self-control, glycemic targets and treatment were based on 
the then-current PDA guidelines. Analysis of the collected data included an assessment of obstetric results based on the 
diagnostic criteria for GDM. Depending on the result of the glucose tolerance test, the patients were divided into subgroups.
Results: 6.28% of births were preterm, and 47% were caesarean. A significant difference was observed in the number of 
preterm births between a subgroups: PDA(+) meeting only criterion 0’ and a PDA(+)meeting only criterion 120’ (16.67% 
vs. 5.83%); and between WHO(+) subgroup meeting only criterion 0’ with respect to the subgroup PDA(+) meeting only 
criterion 0’ (4.69% vs. 16.67%). Significant difference was found in the frequency of LGA between the WHO(-)PDA(+) and 
WHO(+)PDA(-) subgroups (6,57% vs. 14.93%), and between the WHO(-)PDA(+) group and a group of isolated hyperglycemia 
in 60’(6.57% vs. 12.5%). Also a significant positive correlation was observed between birth weight, the occurrence of LGA 
and macrosomia, and maternal weight and BMI before pregnancy.
Conclusions: The results of the analysis indicate the new criteria have greater sensitivity in the prediction of prematurity and 
birth weight. However, it cannot be ruled out that the final results were affected by the therapeutic intervention employed.
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Almost all clinical observations suggest that obstetric 
outcomes in women with gestational diabetes (GDM) are 
not as good as those in the healthy population [1, 2]. 
Cut-off values of blood glucose for the diagnosis of 
GDM were previously based on the risk of developing overt 
type 2 diabetes mellitus (T2 DM) in women after GDM 
(O’Sullivan’s criteria) or used the same cut-off values as for 
the entire population (WHO 1999) [3]. 
The first attempt to determine the impact of maternal 
glycaemia on the developing fetus was a Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) study, a prospective, 
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multicenter and international analysis of data from a mul-
tiethnic group of more than 23,000 pregnant women [4]. 
The results revealed a linear relationship between the val-
ues of glucose identified in the 75 g oral glucose tolerance 
test (75 g OGTT) and birth weight, neonatal hypoglycemia, 
serum C-peptide levels in umbilical cord blood and the 
frequency of caesarean section births [4]. This relationship 
was independent of other factors, i.e. age, body mass index 
(BMI) or a positive family history of diabetes. Based on these 
results, the criterion for the diagnosis of GDM was proposed 
as the presence of glucose values associated with a risk 
factor (OR, odds ratio) of 1.75 for neonatal complications, 
including infant birth weight above the 90th percentile, 
C-peptide concentrations greater than the 90th percentile 
and the fat mass of the newborn above the 90th percentile.
On the basis of this study, the following values for nor-
mal glucose in pregnancy during 75 g OGTT were proposed: 
fasting < 92 mg/dL, at the 60th minute < 180 mg/dL and at 
the 120th minute < 153 mg/dL [5]. In response, in 2013, the 
World Health Organization (WHO) approved new criteria for 
the diagnosis of GDM and recommended their widespread 
use [6]. The Polish Gynecological and Diabetological Associa-
tions (PDA) introduced the new WHO criteria to their clinical 
guidelines in 2014 [7].
As significant differences in the blood glucose reference 
values for the diagnosis of GDM exist between the new and 
the previous PDA criteria, the present study evaluates the 
results obtained from obstetric diabetes centers participat-
ing in the “Dbamy o Mamy” (Caring for Mothers) project, 
according to the diagnostic criteria for GDM used.
MATERIAL AND METHODS
Study group
The study was conducted in the years 2011–2013. A total 
of 2,853 patients from 56 diabetes outpatient clinics in Po-
land took part in this study. All patients were diagnosed with 
GDM in accordance with the PDA recommendations that 
were applicable at that time. The principles of self-control, 
glycemic and therapeutic targets were based on these same 
guidelines.
Testing method
The study was of an observational and prospective 
nature. Data was collected using questionnaires specially 
prepared for the study covering the following domains: 
maternal age, weight before pregnancy and at delivery, 
obstetric history, treatment method of GDM and obstetric 
data on the current pregnancy, incidence of T2 DM amongst 
1st degree relatives and anthropometric data. 
Obstetric data was obtained either during a follow-up 
visit to the clinic or by telephone. The data on neonate was 
based on a discharge summary from hospital and the child’s 
health book.
The following criteria and definitions were used:
 Ū large for gestational age (LGA) — birth weight > 90th 
percentile for specified sex;
 Ū small for gestational age (SGA) birth weight < 5th per-
centile for specified sex;
 Ū macrosomy — birth weight ≥ 4,000 g regardless of the 
duration of pregnancy. 
Assignment to the LGA and SGA categories was based 
on centile charts for the Polish population [8]. According to 
the WHO definitions, on-time labor was considered as one 
which took place between 37 and 42 completed weeks of 
gestation, and premature labour as one that took place 
before 37 completed weeks of gestation.
Group selection and statistical analysis
The study includes a comparative analysis of the criteria 
for the diagnosis of GDM applicable at that time used by the 
Polish Diabetes Association (PDA 2010) and the new criteria 
set by the WHO (WHO 2013). 
The criteria of diagnosis of GDM according to PDA guide-
lines are as follows: 
 Ū fasting plasma glucose > 100 mg/dL (5.6 mmol/L) 
and/or plasma glucose > 140 mg/dL (7.8 mmol/L) 
after 2 hours. 
The criteria of diagnosis of GDM according to WHO 
(2013) guidelines are as follows:
 Ū fasting plasma glucose ≥ 92 mg/dL (5.1 mmol/L) 
and/or plasma glucose > 180 mg/dL (10 mmol/L) 
in the first hour of the test and/or plasma glu-
cose ≥ 153 mg/dL (8.5 mmol/L) after 2 hours. 
For the purpose of the obstetric data analysis, the total 
population of pregnant women was divided into several 
synthetic subgroups according to the diagnostic criteria for 
GDM that were fulfilled:
 Ū PDA(+) group (N = 1,446) — pregnant women who 
fulfilled PDA (2010) criteria, regardless of the WHO 
2013 criteria; 
 Ū WHO(+) group (N = 1,176) — pregnant women who 
fulfilled WHO (2013) criteria, regardless of the PDA (2010) 
criteria;
 Ū PDA(+)/WHO(-) group (N = 337) — pregnant women 
meeting only the PDA (2010) criteria;
 Ū PDA(-)/WHO(+) group (N = 67) — pregnant women 
meeting only the WHO (2013) criteria;
 Ū PDA(+)/WHO(+) group (N = 1,109) — pregnant women 
meeting both the PDA (2010) and WHO (2013) criteria;
 Ū PDA(+) or WHO (+) group — a group comprising all 
patients subjected to statistical analysis (N = 1,513) 
— pregnant women who were diagnosed with GDM 
based on the PDA (2010) or WHO (2013) criteria.
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The primary analysis of the data involved a comparative 
analysis of the current version of the PDA (2010) guidelines 
and the WHO (2013) criteria with regard to time of delivery 
and birth weight. The anthropometric parameters of the preg-
nant mothers and the plasma glucose levels identified by the 
75 g OGTT were also correlated with selected obstetric results.
The results were subjected to statistical analysis. The 
Kolmogorov-Smirnov test was first used to confirm whether 
the variables had a normal distribution. Normally-distribut-
ed dependent and independent variables were compared 
using the Student’s t-test. For variables with a non-normal 
distribution, independent variables were compared with 
the Mann-Whitney U test, and dependent variables with 
the Wilcoxon signed-rank test. Correlations were identified 
with the Pearson’s correlation coefficient for parametric 
variables, and the Spearman’s rank correlation coefficient 
for non-parametric variables. Statistical calculations were 
performed using the PQStat statistical package, license no. 
01500256 (PQStat Software, Poznan, Polska).
RESULTS
The study included 2,853 pregnant women from whom 
completed questionnaires were obtained. For further analy-
sis, 1513 (53.03%) women with complete data were enrolled. 
The characteristics of the study group are shown in Table 1.
The diagnosis of GDM by either WHO or PDA criteria at 
the moment of birth, for term and pre-term deliveries, is 
presented in Table 2.
In the whole group, 93.78% of births took place on term. 
No differences were observed in the duration of pregnancy 
among study groups. Although the incidence of caesar-
ean births (47%) did not differ significantly between crite-
ria subgroups, significantly more caesarean sections were 
recorded in the case of preterm (73.1%) than term births 
(26.9%) (p = 0.0023).
An analysis of pre-term births showed a statistically 
significant difference between the PDA(+) subgroup meet-
ing the sole fasting criterion and the PDA(+) subgroup 
only meeting the 120-minute criterion (p < 0.05). Similarly, 
a significant difference was also observed between the 
WHO(+) subgroup satisfying only the sole fasting criterion 
and the PDA(+) subgroup satisfying the sole fasting criterion 
(p < 0.05). The results of the analysis are presented in Table 3.
Obstetric outcomes regarding birthweight are shown 
in Tables 4–6. 
There were no statistically significant differences regard-
ing SGA and macrosomia.
Higher percentages of LGA, SGA and macrosomia were 
observed in the sub-group of WHO(+) patients with hyper-
glycemia at the 60th minute compared to patients who had 
more than one abnormality in the test. However, this differ-
ence turned out to be statistically insignificant (p > 0.05)
PDA(+) patients with fasting hyperglycaemia had nearly 
twice the rate of LGA and a higher incidence of macroso-
mia than the group with hyperglycaemia after 120 min-
utes. These differences were also apparent when compared 
with patients demonstrating glucose levels above normal 
levels at both time points. Further analysis revealed a weak 
correlation between fasting plasma glucose (FPG) and birth 
weight (Fig. 1). No correlation was observed between the 
glucose concentration after 60 or 120 minutes in 75 g OGTT 
and birth weight. Similarly, no significant correlation was 
found between glucose values at any time during the 75 g 
OGTT test and either LGA, SGA or macrosomia (p > 0.05).
In addition, no significant correlation was observed be-
tween the number of fulfilled diagnostic criteria by which 
GDM was diagnosed and the obstetric results. Similarly, no 
correlation was found between the risk of preterm delivery 
and the presence of glycaemia at any time point nor the 
number of fulfilled criteria. However, a statistically signifi-
cant, but weak, correlation was seen between neonatal birth 
weight and maternal weight before pregnancy (r = 0.162; 
p < 0.0001) (Fig. 2), BMI before pregnancy (r = 0.112; 
Table 1. Anthropometric data of the entire study group
Parameter N = 1513 patients
Age (years) 30.6 ± 4.88
Diagnosis of GDM (week) 28.9 ± 3.24
Body weight before pregnancy [kg] 67.2 ± 14.65
Body weight when diagnosed with GDM [kg] 76.0 ± 14.61
Body weight before delivery [kg] 77.9 ± 14.38
BMI before pregnancy [kg/m2] 24.8 ±5.16
BMI when diagnosed with GDM [kg/m2] 28.1 ± 5.07
BMI before delivery [kg/m2] 28.8 ± 5.07
Multiparous (%) 59.5
History of miscarriage (%) 29.5
Insulin treatment (%) 29.3
Table 2. The incidence of preterm and term deliveries in individual 











or WHO(+) 1513 95 (6.28) 1418 (93.72)
χ2 = 0.539
p = 0.996
PDA(+) 1446  92 (6.36) 1354 (93.64)
WHO(+) 1176 75 (6.38) 1101 (93.62)
PDA(+) 
and WHO(+) 1109 72 (6.49) 1037 (93.51)
PDA(+)WHO(-) 337 20 (5.93) 317 (94.07)
PDA(-)WHO(+) 67 3 (4.48) 64 (95.52)
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Table 3. The incidence of pre-term and term deliveries, depending on when 75OGTT was applied and the number of fulfilled criteria  
for the diagnosis of GDM
Diagnosis of GDM
Pre-term delivery Term delivery
ANOVAWHO(+) patients
N (%) N (%)
Only 0’ criterion (N = 128) 6 (4.69)* 122 (95.31)
χ2 = 1.26
p = 0.51Only 60’ criterion (N = 111) 8 (7.21) 103 (92.79)
Only 120’ criterion (N = 458) 21 (4.59) 437 (95.41)
1 criterion (N = 697) 35 (5.02) 662 (94.98)
χ2 = 9.607
p = 0.0822 criteria (N = 396) 39 (9.85) 357 (90.15)
3 criteria (N = 80) 7 (8.75) 73 (91.25)
PDA(+) patients
p
N (%) N (%)
Only 0’ criterion (N = 36) 6 (16.67)* 30 (83.33)
p = 0.019
Only 120’ criterion (N = 1234) 72 (5.83) 1162 (94.17)
1 criterion (N = 1270) 78 (9.09) 1192 (90.01)
p = 0.52
2 criteria (N = 173) 13 (6.05) 160 (93.95)
*Statistically significant
Table 4. The frequency of SGA, LGA and macrosomia based on PDA and WHO diagnostic criteria for GDM in pregnant women







PDA(+) or WHO(+) 1513 149 (9.87) 135 (8.94) 135 (8.94)
χ2 = 5.85
p = 0.93
PDA(+) 1446 141 (9.77) 125 (8.66) 124 (8.59)
WHO(+) 1176 114 (9.70) 113 (9.62) 105 (8.94)
PDA(+) and WHO(+) 1109 106 (9.57) 103 (9.30) 83 (8.48)
WHO(-)PDA(+) 337 35 (10.45) 22 (6.57)* 30 (8.96)
WHO(+)PDA(-) 67 8 (11.94) 10 (14.93)* 11 (16.42)
Isolated WHO(+) 60’ PDA(-) 48 6 (12.5) 6 (12.5)* 8 (16.67)
*Statistically significant
Table 5. The child’s birth weight for the WHO (+) GDM patients diagnosed by OGTT according to time and number of fulfilled criteria







Only 0’ criterion 128 10 (7.81) 12 (9.38) 8 (6.25)
χ2 = 3.06
p = 0.54
Only 60’ criterion 111 13 (11.71) 15 (13.51) 13 (11.71)
Only 120’ criterion 458 42 (9.17) 43 (9.39) 39 (8.52)
1 criterion 697 65 (9.33) 70 (10.04) 60 (8.61)
2 criteria 396 48 (12.12) 44 (11.11) 45 (11.36)
3 criteria 80 13 (16.25) 6 (7.50) 8 (10.00)
Table 6. The child’s birth weight, for the PDA (+) GDM patients diagnosed by OGTT according to time and number of fulfilled criteria







Only 0’ criterion 36 6 (16.67) 2 (5.56) 4 (11.11) χ2 = 2.95
p = 0.22Only 120’ criterion 1234 100 (8.10) 127 (10.29) 108 (8.75)
1 criterion 1270 106 (8.35) 129 (10.16) 112 (8.82) χ2 = 3.72
p = 0.1552 criteria 173 19 (10.98) 12 (6.94) 11 (6.36)
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p < 0.0001) and the relative weight gain during pregnancy 
defined as the quotient of the weight gain by weight before 
pregnancy in kilograms (r = 0.118; p < 0.001). A positive cor-
relation was observed between the occurrence of LGA and 
maternal weight before pregnancy (r = 0.156; p < 0.0001), 
BMI before pregnancy (r = 0.13; p < 0.0001) and BMI before 
delivery (r = 0 11; p < 0.0001). The mother’s body weight be-
fore pregnancy also correlated positively with macrosomia 
(r = 0.121; p <0.0001).
DISCUSSION 
Before 2013, WHO guidelines recommended the same 
cut-off values for the diagnosis of diabetes in pregnant 
women as in the entire population. However, this choice of 
criterion seemed to be inappropriate as hormonal changes 
during pregnancy alter carbohydrate metabolism: physiolo- 
gically lower fasting and higher postprandial plasma glucose 
values are found during pregnancy. It remained unclear 
whether and to what extent these slight differences in glu-
cose concentration may affect the fetus, especially since 
glucose is only one of many factors influencing the devel-
opment of the fetus. The Atlantic Study points to factors 
such as obesity, genetic factors, smoking and the presence 
of co-morbidities, and therefore, any assessment of direct 
glucose participation was problematic, as was establish-
ing acceptable glucose levels during pregnancy. However, 
prospective analysis of prenatal blood glucose values in 
the HAPO study demonstrated the continuous nature of 
the impact of maternal glycaemia on parameters such as 
birth weight, the C-peptide concentration in cord blood 
or neonatal risk of hypoglycaemia. The results of this study 
became the basis for the development of new guidelines, 
which lowered the cut-off value for diagnosis of GDM for 
fasting glucose levels while simultaneously increasing value 
for blood glucose 2 hours after an oral glucose load, com-
pared to WHO criteria. It was also found that exceeding only 
one of the three plasma glucose levels in an OGTT during 
pregnancy carries the same risks for the newborn as increas-
ing two or three values.
The present study is a prospective analysis of the ob-
stetric outcome of women with GDM diagnosed according 
to the PDA criteria, by evaluating the degree to which the 
application of the new WHO (2013) criteria would affect the 
obstetric results observed in the population. In this study, 
94% of all patients delivered on term, and no difference was 
observed between the incidence of prematurity between 
the assessed groups, regardless of the criterion used, and the 
fulfilled GDM diagnostic criteria. Analysis of the moment of 
birth, depending on the time point when the blood glucose 
was elevated showed a statistically significant difference 
only between a subset of the WHO(+) only met the fasting 
criterion (more than 92 mg/dL [5.1 mmol/L]), and a similar 
subgroup of PDA(+) fulfilled the fasting criterion (above 
100 mg/dL [5.6 mmol/L]). This demonstrates the critical role 
of fasting glucose on the course of fatal development. How-
ever correlation analysis showed no relationship between 
the risk of preterm delivery and the presence of glycaemia 
at any time point nor the number of fulfilled criteria. The 
results of our analysis are similar to those in the HAPO study, 
in which the rate of preterm births was 6.9% and the OR 
for preterm delivery was comparable to glucose levels at 
all three time points.
Our findings concerning the fulfilled diagnostic criteria 
indicated higher frequencies of LGA, SGA and macrosomia in 
the WHO(+)PDA(-) group but the only statistically significant 
differences were found with regard to LGA between WHO(+)
PDA(-) and WHO(-)PDA(+) groups as well as between the 
WHO(-)PDA(+) group and a group with isolated hypergly-
caemia in the first hour of the test (both p < 0.05). 
Hence, pregnant mothers who met the diagnostic 
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Figure 1. The correlation between maternal fasting plasma glucose 
and neonatal birth weight within the whole studied group
Figure 2. The correlation of maternal body weight (before 
pregnancy) with neonatal body weight in the whole studied group
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above 100 mg/dL, more often gave birth to children with 
macrosomia, which confirms that FPG has a considerable 
impact on the induction of excessive fetal growth. This is 
further confirmed by the fact that in the group in which GDM 
diagnosis was based on blood glucose above 92 mg/dL, 
the incidence of LGA was almost half this value. Therefore, 
the updated WHO guidelines are justified in introducing 
changes such as a reduction in FPG value, with a simulta-
neous increase in post-load glucose criterion and adding 
a criterion after 1 hour. 
In the total group, 48 patients with isolated hypergly-
caemia above 180 mg/dL (10 mmol/L) were identified in 
the first hour of the test. The percentage of LGA, SGA and 
macrosomia were also higher in this group, although not 
so significantly, than in fasting patients or those in the 2nd 
hour of hyperglycaemia, regardless of the adopted PDA 
or WHO criterion. It remains uncertain whether any of the 
glucose values identified by 75 g OGTT are more applicable 
for estimating the risk of complications and determination 
of medical goals. LGA most common occurred in the group 
of patients meeting the fasting plasma glucose PDA crite-
rion (16.67%), and the least so in those fulfilling the fasting 
WHO criterion (7.81%) for all time points when abnormal 
glycaemia was found (0, 60, and 120 minutes).
This difference is not surprising because deeper meta-
bolic disorders might be expected at the higher cut-off 
values for FPG in the PDA criterion (100 mg/dL), with conse-
quently worse obstetric results. Correlation analysis showed 
no dependence between glucose values, including FPG, and 
the incidence of LGA, macrosomia or prematurity.
In the WHO(+) patients, the greatest percentage of the 
LGA, and macrosomia was observed in the subgroup with 
hyperglycaemia identified in the 60th minute of 75 g OGTT 
— both in comparison to the other time points (isolated 
or not), and compared to patients who met 2 or 3 criteria. 
In the PDA(+) patients, the highest percentage of LGA and 
macrosomia was observed in patients with identified fast-
ing hyperglycaemia. However, these differences were not 
statistically significant. In the HAPO study, glucose in the first 
hour of 75 g OGTT, after taking into consideration other fac-
tors, was found to be the only predictor of clinical neonatal 
hypoglycaemia, while fasting blood glucose proved to be 
the strongest predictor of elevated levels of C-peptide in 
umbilical blood [4]. 
A review of Polish studies by Zawiejska et al. indicates 
the presence of fasting hyperglycaemia as a predictor of 
increased risk of obstetric complications. Fasting hyper-
glycaemia, based on WHO criteria, was associated with 
poor metabolic control, a more frequent need to initiate 
insulin therapy, and increased incidence of macrosomia, 
while hyperglycaemia after 2 hours was associated only with 
a higher frequency of pregnancy-induced hypertension [9]. 
The correlation analysis in the present study revealed no 
significant correlation between the number of fulfilled dia- 
gnostic criteria in subsequent time points and the obstetric 
results. A study by Ferrara, also conducted in a multi-ethnic 
group, found an increased risk of macrosomia, hypoglycae-
mia, and neonatal hyperbilirubinaemia to be associated 
with an increased chance of abnormal blood glucose values 
according to the American Diabetes Association guidelines 
of the time [10].
The results of the correlation analysis in this study found 
no relationship between neonatal birth weight and the con-
centration of glucose at any time point. However, the HAPO 
study reports a strong linear positive correlation between 
glucose concentration and neonatal birth weight and the 
concentration of C-peptide in the umbilical cord blood. The 
authors clearly determined cut-off values at which the risk 
should be considered elevated. A slightly weaker relation-
ship was observed in relation to the incidence of preeclamp-
sia, preterm delivery, caesarean sections, perinatal injuries, 
clinical neonatal hypoglycaemia, jaundice and the need for 
neonatal intensive supervision [4]. Hence, the prior criteria 
do not reflect the real risk of perinatal complications and 
did not have sufficient sensitivity for identifying pregnant 
women with an increased risk of perinatal complications.
A recently published Danish study conducted in women 
with mild glucose intolerance also found a linear relation-
ship between plasma glucose level and 2-h 75 g OGTT score 
and pregnancy complications including frequency of cae-
sarean sections, premature births, incidence of shoulder 
dystocia and macrosomia [2]. Another analysis of the same 
group found a linear relationship between fasting glucose 
and the incidence of macrosomia [1]. Similarly, a study con-
ducted in the United States in an ethnically diverse group 
found a linear relationship between blood glucose levels, 
both fasting and after two hours, and macrosomia [11].
The undesirable effects of hyperglycaemia in the fetal 
period not only result in an increased risk of obstetric com-
plications. Long-term observations suggest that children 
with LGA are characterized by a higher incidence of glucose 
intolerance, diabetes and obesity later in life, and girls of 
mothers with GDM have an increased risk of GDM in the 
future [12–14]. Ogonowski et al. report that low birthweight 
in girls constituted a risk factor for gestational diabetes, 
and high birth weight increased the risk of obesity in the 
periconceptional period [15].
The new, stricter WHO criteria were met with skepti-
cism, particularly concerning the costs and benefits of 
the adopted therapeutic strategies to women with mild 
hyperglycaemia. Other studies, however, seem to justify 
tightening the criteria. The results of the Australian Carbo-
hydrate Intolerance Study in Pregnant Women (ACHOIS) 
study indicate that treatment of gestational diabetes re-
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duces perinatal morbidity and improves the quality of life 
in relation to health status [16]. The intervention group 
demonstrated significantly lower rates of serious perinatal 
complications. In addition, the children had significantly 
lower mean birth weight, a significantly smaller percentage 
had LGA or macrosomia, and no difference was found in the 
incidence of births with SGA. This group also demonstrated 
lower weight gain during pregnancy and a reduced inci-
dence of pre-eclampsia. However, the intervention group 
also demonstrated a higher incidence of indications for 
inductions of labor, the children were born slightly earlier, 
and a higher percentage of children were admitted to the 
neonatal unit, with a similar incidence of caesarean sec-
tions. The authors suggest that the more frequent need for 
induction of labor and increased supervision of the newborn 
could be due to greater awareness of patient illness by 
the physician and a greater propensity to intervene. The 
authors conclude that the more frequent induction of labor 
and greater number of earlier births at least partly account 
for the reduced mean birth weight and lower incidence of 
preeclampsia in the intervention group. 
The study showed that treatment of patients even with 
mild hyperglycaemia benefits not only the mother but the 
child too: less weight gain during pregnancy may increase 
the chance of returning to normal body weight after birth, 
resulting in a lower risk of future metabolic disorders. On the 
other hand, the literature data suggests that hyperglycaemia 
in the fetal period significantly influences the risk of meta-
bolic complications for offspring in later life [12–14]. The 
results of a British study conducted by the National Institute 
of Health evaluating the cost and effectiveness of health 
care for patients with GDM indicate that screening, diagno-
sis and treatment of gestational diabetes is effective [17]. 
Another randomized study also found that although treat-
ing mild hyperglycaemia appears to have beneficial effects 
on the risk of macrosomia, shoulder dystocia, frequency of 
caesarean delivery, preeclampsia and hypertension com-
pared to a control group, no differences were observed 
between the groups regarding the incidence of the com-
posite endpoint of perinatal death, hyperbilirubinaemia, hy-
poglycaemia, hyperinsulinaemia and perinatal injuries [18]. 
The efficacy of treating GDM has also been demonstrated 
in other studies [19].
Available studies on the impact of maternal hyper-
glycaemia on obstetric outcome are limited by the fact 
that they involve groups of patients diagnosed with GDM, 
without any representative control population of healthy 
women. It should be emphasized that the present study, 
like the majority of published studies, evaluates the results 
of women diagnosed with hyperglycaemia, thus obtaining 
adequate glycaemic data, while referring them to a popula-
tion of healthy pregnant women. The authors of the HAPO 
study indicate that one key limitation of the study is that no 
results were available regarding the nutritional status and 
gestational weight gain of women, which may account for 
the differences observed between the HAPO results and 
our present analysis. In addition, indications for caesar-
ean section may have resulted from factors such as maternal 
BMI, previous gestational diabetes or previously diagnosed 
macrosomia. In Polish conditions, maternal preferences dur-
ing pregnancy also are a major factor, which is why way of 
terminating the pregnancy seems to be burdened with too 
big error to be able to conclude on this basis. 
It has been estimated that the number of women diag-
nosed with GDM would rise following the implementation 
of new WHO guidelines in 2013. In the HAPO study, the 
mean incidence of GDM was 17.8% based on the new crite-
ria. To date, no data exists on the actual number of women 
with GDM in the Polish population. Due to the expected 
enlargement of the population of women diagnosed with 
GDM who will require specialist care, it seems reasonable 
to examine the efficacy and costs in accordance with the 
new guidelines and the implementation of individualized 
education and self-control. Time will reveal the health effects 
and costs of the newly-introduced GDM diagnostic criteria.
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